Nafamostat mesylate inhibits coagulation and fibrinolysis.
Nafamostat is caused by inactivating action on thrombin, plasmin, trypsin, kallikrein, coagulation factors XIIa and Xa, complements C1r and C1s1,2.
Initial sequestration of activated neutrophils and platelet microaggregates in capillaries are responsible for the inflammatory response associated with cardiopulmonary bypass.
1. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor
(FUT-175) on the coagulation system. Haemostasis 1985;15: 164-168.
2. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981 13; 661:342-345.
3. KENEI FURUKAWA, et al. Prognostic Factors of Unresectable Pancreatic Cancer Treated with Nafamostat Mesilate Combined with Gemcitabine Chemotherapy. Research November 2012 vol. 32 no. 11 5121-5126.